GSK/Corixa Bexxar cmte. review?
Executive Summary
GlaxoSmithKline/Corixa's Bexxar (tositumomab) is slated for review for treatment of low-grade or transformed low-grade non-Hodgkin's lymphoma by FDA's Oncologic Drugs Advisory Committee at the tentatively scheduled Dec. 17-18 meeting. Corixa requested committee review of the drug in its appeal of a March 12 "complete response" letter (1"The Pink Sheet" May 20, In Brief). The company has said it expected a review of Bexxar before year-end (2"The Pink Sheet" Aug. 12, In Brief)...
You may also be interested in...
AstraZeneca Casodex FDA Cmte. To Focus On Efficacy Differences In Trials
AstraZeneca expects FDA's Oncologic Drugs Advisory Committee's Casodex review to focus on the apparent lower efficacy of the prostate cancer drug in U.S. trials compared to those outside the U.S
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.